In the process of developing this regimen, we had previously shown that adding IT-IC and anti-CTLA-4 mAb to 12 Gy of RT did not significantly slow tumor growth, or prolong survival, over the 12 Gy of RT alone. The gene discussed is CTLA4; the disease is neoplasm.